Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR2 V564I |
| Therapy | Pemigatinib |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR2 V564I | Advanced Solid Tumor | predicted - sensitive | Pemigatinib | Preclinical - Biochemical | Actionable | In a preclinical study, Pemazyre (pemigatinib) treatment inhibited activity of FGFR2 V564I in a kinase assay (PMID: 36698015). | 36698015 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (36698015) | Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants. | Full reference... |